Search

Your search keyword '"Loaec, Cecile"' showing total 16 results
Start Over Author "Loaec, Cecile"
16 results on '"Loaec, Cecile"'

4. Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.

Author

Classe, Jean-Marc, primary, Campion, Loic, additional, Lecuru, Fabrice, additional, Vergote, Ignace, additional, Jankowski, Clémentine, additional, Wernert, Romuald, additional, Pomel, Christophe, additional, Houvenaeghel, Gilles, additional, Dupre, Pierre-Francois, additional, Mathevet, Patrice, additional, Villet, Richard, additional, Joly, Florence, additional, Berton, Dominique, additional, Debeaupuis, Emilie, additional, Frenel, Jean-Sebastien, additional, and Loaec, Cecile, additional

Published
2024
Full Text
View/download PDF

9. #438 Molecular alterations predictive of outcome in early staged cervical cancer : a translational investigation from the SENTICOL III trial

Author

Gani, Maryame El, primary, Ibadioune, Sabrina, additional, Beaino, Zakhia El, additional, Vacher, Sophie, additional, Degnieau, Alexandre, additional, Jeannot, Emmanuelle, additional, Masliah-Planchon, Julien, additional, Vincent-Salomon, Anne, additional, Ferron, Gwenael, additional, Golfier, François, additional, Lambaudie, Eris, additional, Narducci, Fabrice, additional, Loaec, Cecile, additional, Uzan, Jennifer, additional, Marchal, Fredéric, additional, Plante, Marie, additional, Mathevet, Patrice, additional, Kamal, Maud, additional, Lecuru, Fabrice, additional, and Bièche, Ivan, additional

Published
2023
Full Text
View/download PDF

11. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study

Author

Classe, Jean-Marc, Loaec, Cecile, Gimbergues, P., Alran, S., de Lara, C. Tunon, Dupre, P. F., Rouzier, Roman, Faure, C., Paillocher, N., Chauvet, M. P., Houvenaeghel, G., Gutowski, M., De Blay, P., Verhaeghe, J. L., Barranger, E., Lefebvre, C., Ngo, C., Ferron, G., Palpacuer, C., and Campion, L.

Published
2019
Full Text
View/download PDF

12. 2022-RA-858-ESGO Benefit of bevacizumab according to CA125 decline kinetic in first-line high grade serous ovarian carcinoma (HGSOC) patients in real-life setting

Author

Becker, Ondine, primary, Chevrier, Marion, additional, Gladieff, Laurence, additional, Joly, Florence, additional, Toussaint, Philippe, additional, Floquet, Anne, additional, Pomel, Christophe, additional, Costaz, Helene, additional, Kfoury, Maria, additional, Rouge, Thibault de la Motte, additional, Sabatier, Renaud, additional, Loaec, Cecile, additional, Leblanc, Eric, additional, Marchal, Frederic, additional, Colombo, Pierre-Emmanuel, additional, Barranger, Emmanuel, additional, Colomban, Olivier, additional, Bosquet, Lise, additional, Rodrigues, Manuel, additional, and You, Benoit, additional

Published
2022
Full Text
View/download PDF

14. Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study

Author

Classe, Jean-Marc, primary, Loaec, Cecile, additional, Gimbergues, P., additional, Alran, S., additional, de Lara, C. Tunon, additional, Dupre, P. F., additional, Rouzier, Roman, additional, Faure, C., additional, Paillocher, N., additional, Chauvet, M. P., additional, Houvenaeghel, G., additional, Gutowski, M., additional, De Blay, P., additional, Verhaeghe, J. L., additional, Barranger, E., additional, Lefebvre, C., additional, Ngo, C., additional, Ferron, G., additional, Palpacuer, C., additional, and Campion, L., additional

Published
2018
Full Text
View/download PDF

15. Surgical management of Low-Grade Serous Carcinoma of the ovary: Results of a multicenter study from The French National Network dedicated to Ovarian Malignant Rare Tumors (TMRO)

Author

Panchbhaya, Nabilah, Bats, Anne-Sophie, Bonsang-Kitzis, Hélène, Ray-Coquard, Isabelle, Lauraine, Eric Pujade, Colombo, Emmanuel, Fabbro, Michel, Rouzier, Roman, Pautier, Patricia, Le Gall, Edouard, Classe, Jean-Marc, Loaec, Cécile, Floquet, Anne, Guyon, Frédéric, Babin, Guillaume, Lanse, Frédéric, Renaudin, Manon, Joly, Florence, Huchon, Cyrille, Dubot, Caroline, Provansal, Magali, Lavau-Denes, Sandrine, Pomel, Christophe, Cornou, Caroline, Augereau, Paule, Lecomte, Laurence Lancry, Kurtz, Jean-Emmanuel, Remoue, Pascale, Sterkers, Nicolas, Uzan, Catherine, Marchand, Eva, Nadeau, Cédric, Iurisci, Ida, Barletta, Hugues, Aleba, Albert, Blanchot, Jérôme, Rudigoz, René-Charles, Philip, Charles-André, and Lecuru, Fabrice

Published
2019
Full Text
View/download PDF

16. Survival Outcomes after Hyperthermic Intraperitoneal Chemotherapy for a First Ovarian Cancer Relapse: A Systematic Evidence-Based Review.

Author

Classe, Jean-Marc, Asselain, Bernard, Campion, Loic, Berton, Dominique, Frenel, Jean-Sébastien, Lécuru, Fabrice, Ferron, Gwenael, Gladieff, Laurence, Bourgin, Charlotte, and Loaec, Cecile

Subjects
SURGICAL complication risk factors, ABDOMINAL surgery, MORTALITY risk factors, ADJUVANT chemotherapy, OVARIAN tumors, THERMOTHERAPY, SYSTEMATIC reviews, CANCER relapse, CANCER patients, TREATMENT effectiveness, SURVIVAL analysis (Biometry), DIGESTIVE organ surgery, COMBINED modality therapy, MEDLINE
Abstract

Simple Summary: Since 2000, scientific literature has recommended the use of hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of ovarian cancer relapse. This treatment, combining heavy abdominal surgery and intraperitoneal heated chemotherapy is associated with a risk of post-operative death and severe morbidity. Previous systematic reviews of the scientific literature concluded that HIPEC was effective for improving patient survival following a first relapse of ovarian cancer. This current systematic review, emphasizing the level of evidence of the published series, using the Oxford levels of evidence grading system, has made it possible to analyze the weaknesses of this scientific literature. This literature is characterized by biases—such as patient inclusion, and weak methods—such as retrospective patient collection, a small number of included patients, and no statistical hypothesis. As a results, HIPEC must remain an experimental procedure in ovarian cancer relapse, patients until there are positive results from ongoing clinical trials. Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is routinely used in the treatment of a first ovarian cancer relapse. Methods: This systematic review, in accordance with Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, aimed to assess the quality of scientific proof of the survival benefits of HIPEC, using Medline and Google Scholar. Qualitative analysis using the Oxford CEBM Levels of Evidence 2011 grading is reported. Results: Of 469 articles identified, 23 were included; 15 based on series of patients treated with HIPEC without a control group, and 8 case control series of patients treated with or without HIPEC. The series without a control group showed median overall survival (OS) ranged from 23.5 to 63 months, highlighting a broad standard deviation. Considering the case control series, OS was significantly better in the HIPEC group in 5 studies, and similar in 1. The current review showed considerable heterogeneity and biases, with an Oxford Level of Evidence grading of 4 for 22 selected series and 2 for one. Conclusions: There is no strong evidence to suggest efficacy of HIPEC in improving survival of patients treated for a first relapse of ovarian cancer due to the low quality of the data. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results